Serotonin and Serotonin Receptors in Hallucinogen Action

Handbook of Behavioral Neuroscience

Volumn 21, Issue C, 2010, Pages 621-636

  Halberstadt, Adam L ^a   Nichols, David E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

5 HT2A receptor; behavior; drug discrimination; entactogen; hallucinogen; head twitch; locomotor activity; MDMA; prepulse inhibition; psychedelic

Indexed keywords

EID: 85009191630     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-7339(10)70103-X     Document Type: Chapter

References (151)

1. L. Adams M.A. Geyer Effects of DOM and DMT in a proposed animal model of hallucinogenic activity Prog. Neuropsychopharmacol. Biol. Psychiatry 9 1985 121 132
2. L. Adams M.A. Geyer A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats Behav. Neurosci. 99 1985 881 900
3. GK. Aghajanian W.E. Foote ME. Sheard Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe Science 161 1968 706 707
4. G.K. Aghajanian W.E. Foote ME. Sheard Action of psychotogenic drugs on midbrain raphe neurons J. Pharmacol. Exp. Ther. 171 1970 178 187
5. J.B. Appel KA. Cunningham The use of drug discrimination procedures to characterize hallucinogenic drug actions Psychopharmacol. Bull. 22 1986 959 967
6. 2 agonists in rats Pharmacol. Toxicol. 64 1989 165 172
7. 2 agonist DOI Eur. J. Pharmacol. 161 1989 45 51
8. 2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats Psychopharmacology 181 2005 676 687
9. 2 receptors Brain Res. 994 2003 203 215
10. M.H. Baumann R.D. Clark R.B. Rothman Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain Pharmacol. Biochem. Behav. 90 2008 208 217
11. D. Bengel D.L. Murphy A.M. Andrews C.H. Wichems D. Feltner A. Heils R. Môssner H. Westphal K.P. Lesch Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in serotonin transporter-deficient mice Mol. Pharmacol. 53 1998 649 655
12. H.H. Berendsen C.L. Broekkamp Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice Br. J. Pharmacol. 101 1990 667 673
13. D. Biello Not imagining it. Research into hallucinogens cautiously resumes. Sci. Am. 295 2006 33 35
14. J.B. Blair D. Kurrasch-Orbaugh D. Marona-Lewicka M.G. Cumbay V.J. Watts E.L. Barker D.E. Nichols Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines J. Med. Chem. 43 2000 4701 4710
15. M.R. Braden Towards a biophysical understanding of hallucinogen action. PhD Dissertation 2007 Purdue University West Lafayette, IN
16. 2A receptor Mol. Pharmacol. 72 2007 1200 1209
17. R.W. Brimblecombe Effects of psychotropic drugs on open-field behavior in rats Psychopharmacologie 4 1963 139 147
18. 2 – like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA Psychopharmacology 173 2004 326 336
19. 1C receptor agonist J. Pharmacol. Exp. Ther. 258 1991 891 896
20. C.W. Callaway L.L. Wing M.A. Geyer Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats J. Pharmacol. Exp. Ther. 254 1990 456 464
21. O.L. Carter F. Hasler J.D. Pettigrew G.M. Wallis G.B. Liu F.X. Vollenweider Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans Psychopharmacology 195 2007 415 424
22. M. Cohen H. Wakeley A comparative behavioral study of ditran and LSD in mice, rats, and dogs Arch. Int. Pharmacodyn. 173 1968 316 325
23. F.C. Colpaert Cross generalization with LSD and yohimbine in the rat Eur. J. Pharmacol. 102 1984 73 77
24. F.C. Colpaert P.A.J. Janssen A characterization of the LSD-antagonist effects of pirenperone in the rat Neuropharmacology 22 1983 1001 1003
25. F.C. Colpaert G.J.E. Niemegeers P.A.J. Janssen A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist J. Pharmacol. Exp. Ther. 221 1982 206 214
26. S.J. Corne R.W. Pickering A possible correlation between drug-induced hallucinations in man and a behavioural response in mice Psychopharmacologia 11 1967 65 78
27. 2 receptors? Pharmacol. Biochem. Behav. 36 1990 901 906
28. C. DeMontigny G.K. Aghajanian Preferential action of 5-methoxytryptamine and 5-methoxydimethyltryptamine on presynaptic serotonin receptors: a comparative iontophoretic study with LSD and serotonin Neuropharmacology 16 1977 811 818
29. A. Dittrich The standardized psychometric assessment of altered states of consciousness (ASCs) in humans Pharmacopsychiatry 31 Suppl. 2 1998 80 84
30. S.C. Dulawa M.A. Geyer Psychopharmacology of prepulse inhibition in mice Chin. J. Physiol. 39 1996 139 146
31. 2 receptors mediate discrete behaviors in the Mongolian gerbil Pharmacol. Biochem. Behav. 43 1992 131 137
32. 2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis Psychopharmacology 121 1995 347 356
33. P.J. Fletcher K.M. Korth S.R. Robinson G.B. Baker Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement Psychopharmacology 162 2002 282 291
34. J.H. Gaddum Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine J. Physiol. (Lond.) 121 1953 15P
35. M.A. Geyer Approaches to the characterization of drug effects on locomotor activity in rodents M.W. Adler A. Cowan Modern Methods in Pharmacology: Testing and Evaluation of Drugs of Abuse 1990 Wiley-Liss New York, NY 81 99
36. M.A. Geyer R.K. Light G.J. Rose L.R. Petersen D.D. Horwitt L.M. Adams R.L. Hawkins A characteristic effect of hallucinogens on investigatory responding in rats Psychopharmacology 65 1979 35 40
37. 2 agonists or antagonists? Neuropsychopharmacology 3 1990 509 517
38. R.A. Glennon B.R. Misenheimer Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline Pharmacol. Biochem. Behav. 33 1989 909 912
39. 1A serotonin agonist 8-hydroxy-2-(di-n-propylamino)tetralin Pharmacol. Biochem. Behav. 66 2000 483 488
40. R.A. Glennon J.A. Rosecrans R. Young The use of the drug discrimination paradigm for studying hallucinogenic agents. A review F.C. Colpaert J.L. Slangen Drug Discrimination: Applications in CNS Pharmacology 1982 Elsevier Biomedical Press Amsterdam 69 96
41. 2 antagonists Eur. J. Pharmacol. 91 1983 189 196
42. 2 involvement in the mechanisms of action of hallucinogenic agents Life Sci. 35 1984 2505 2511
43. R.A. Glennon R. Higgs R. Young H. Issa Further studies on N-methyl-1(3,4-methylenedioxyphenyl)-2-aminopropane as a discriminative stimulus: antagonism by 5-hydroxytryptamine3 antagonists Pharmacol. Biochem. Behav. 43 1992 1099 1106
44. L.H. Gold G.F. Koob M.A. Geyer Stimulant and hallucinogenic behavioral profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats J. Pharmacol. Exp. Ther. 247 1988 547 555
45. L.H. Gold C.B. Hubner G.F. Koob A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA Psychopharmacology 99 1989 40 47
46. 2A receptor-mediated signaling pathways to affect behavior Neuron 53 2007 439 452
47. E. Gouzoulis-Mayfrank B. Thelen E. Habermeyer H.J. Kunert K.A. Kovar H. Lindenblatt L. Hermle M. Spitzer H. Sass Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology 142 1999 41 50
48. E. Gouzoulis-Mayfrank K. Heekeren A. Neukirch M. Stoll C. Stock M. Obradovic K.A. Kovar Psychological effects of (S)-ketamine and, N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers Pharmacopsychiatry 38 2005 301 311
49. 5A receptor Neuron 22 1999 581 591
50. R. Griffiths W. Richards U. McCann R. Jesse Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology 187 2006 268 283
51. R. Griffiths W. Richards M. Johnson R. McCann U and Jesse Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later J. Psychopharmacol. 22 2008 621 632
52. H.J. Haigler G.K. Aghajanian Mescaline and LSD: direct and indirect effects on serotonin-containing neurons in brain Eur. J. Pharmacol. 21 1973 53 60
53. H.J. Haigler G.K. Aghajanian Lysergic acid diethylamide and serotonin: a comparision of effects on serotonergic neurons and neurons receiving a serotonergic input J. Pharmacol. Exp. Ther. 188 1974 688 699
54. A.L. Halberstadt M.R. Buell V.L. Masten V.B. Risbrough M.A. Geyer Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors Psychopharmacology 201 2008 55 66
55. F. Hasler U. Grimberg M.A. Benz T. Huber F.X. Vollenweider Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study Psychopharmacology 172 2004 145 156
56. F. Hasler E. Studerus K. Lindner S. Ludewig F. Vollenweider Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA J. Psychopharmacol 2008 10.1177/0269881108094650
57. L. Hermle M. Fünfgeld G. Oepen H. Botsch D. Borchardt E. Gouzoulis R.A. Fehrenbach M. Spitzer Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research Biol. Psychiatry 32 1992 976 991
58. L. Hermle M. Spitzer D. Borchardt K.A. Kovar E. Gouzoulis Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8 1993 171 176
59. I.D. Hirschhorn J.C. Winter Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli Psychopharmacologia 22 1971 64 71
60. A.J. Hoffman D.E. Nichols Synthesis and LSDlike discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid, N,N-diethylamide derivatives J. Med. Chem. 28 1985 1252 1255
61. H. Isbell C.R. Logan Studies on the diethylamide of lysergic acid (LSD-25). II. Effects of chlorpromazine, aza-cyclonol, and reserpine on the intensity of the LSD-reaction AMA Arch. Neurol. Psychiatry 77 1957 350 358
62. H. Isbell C.R. Logan E.J. Miner Studies on lysergic acid diethylamide (LSD-25). III. Attempts to attenuate the LSD-reaction in man by pretreatment with neurohumoral blocking agents AMA Arch. Neurol. Psychiatry 81 1959 20 27
63. C. Johansson D.M. Jackson J. Zhang L. Svensson Prepulse inhibition of acoustic startle, a measure of sensorimotor gating: effects of antipsychotics and other agents in rats Pharmacol. Biochem. Behav. 52 1995 649 654
64. 3H]dopamine release from superfused rat brain slices Eur. J. Pharmacol. 132 1986 269 276
65. J. Kabes Z. Fink Z. Roth A new device for measuring spontaneous motor activity-effects of lysergic acid diethylamide in rats Psychopharmacologia 23 1972 75 85
66. J.H. Kehne R.A. Padich T.C. McCloskey V.L. Taylor C.J. Schmidt 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats Psychopharmacology 124 1996 95 106
67. N. Khorana M.R. Pullagurla R. Young R.A. Glennon Comparison of the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) and cocaine: asymmetric generalization Drug Alcohol Depend. 74 2004 281 287
68. 1C receptors Neurosci. Biobehav. Rev. 16 1992 95 105
69. 1A receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats, Behav Pharmacol. 7 1996 551 559
70. 2 receptors in rats Psychopharmacology 140 1998 69 74
71. 2C receptors Neuropsychopharmacology 18 1998 339 351
72. 2 receptors in the effects of 5-MeO-DMT on locomotor activity and pre-pulse inhibition in rats Psychopharmacology 189 2006 319 329
73. 2 receptor studies Neuropsychopharmacology 3 1990 361 369
74. 2A agonist activity Behav. Pharmacol. 18 2007 283 288
75. M.E. Liechti F.X. Vollenweider The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers J. Psychopharmacol. 14 2000 269 274
76. M.E. Liechti F.X. Vollenweider Acute psychological and physiological effects of MDMA (‘Ecstasy’) after haloperidol pretreatment in humans Eur. Neuropsychopharmacol. 10 2000 289 295
77. M.E. Liechti C. Baumann A. Gamma F.X. Vollenweider Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) are attenuated by the serotonin uptake inhibitor citalopram Neuropsychopharmacology 22 2000 513 521
78. 2 antagonist ketanserin in healthy humans Neuropsychopharmacology 23 2000 396 404
79. M.E. Liechti M.A. Geyer D. Hell F.X. Vollenweider Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin Neuropsychopharmacology 24 2001 240 252
80. 2 receptors Psychopharmacology 188 1986 525 526
81. R.S. Mansbach D.L. Braff M.A. Geyer Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat Eur. J. Pharmacol. 167 1989 49 55
82. 2-adrenoceptor agonists and antagonists Psychopharmacology 120 1995 384 391
83. D. Marona-Lewicka R.A. Thisted D.E. Nichols Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis Psychopharmacology 180 2005 427 435
84. 4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI Psychopharmacology 2008 10.1007/s00213-008-1238-0
85. 1B/1D receptors J. Pharmacol. Exp. Ther. 290 1999 965 973
86. T.F. Meert Serotonin mechanisms in antipsychotic treatment: evidence from drug discrimination studies J.M. Kane H.J. Môller F. Awouters Serotonin in Antipsychotic Treatment. Mechanisms and Clinical Practice 1996 Marcel Dekker, Inc. New York, NY 109 130
87. 2 antagonists: a preclinical evaluation of possible therapeutic effects C. Idzikowski P.J. Cowen Serotonin, Sleep and Mental Disorders 1991 Washington Biomedical Publishing 65 76
88. T.F. Meert P.L.A.J. DeHaes P.C.M. Vermote P.A.J. Janssen Pharmacological validation of ritanserin and risperidone in the drug discrimination test procedure in the rat Drug Dev. Res. 19 1990 353 373
89. M.J. Millan F.C. Colpaert Methylenedioxymeth amphetamine induces spontaneous tail-flicks in the rat via 5-HT1A receptors Eur. J. Pharmacol. 193 1991 145 152
90. S.M. Mittman M.A. Geyer Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol Psychopharmacology 105 1991 69 76
91. F.A. Moreno C.B. Wiegand E.K. Taitano P.L. Delgado Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder J. Clin. Psychiatry 67 2006 1735 1740
92. 1A receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat Prog. Neuropsychopharmacol. Biol. Psychiatry 29 2005 648 657
93. 2C receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 359 1999 1 6
94. D.E. Nichols Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens J. Psychoactive Drugs 18 1986 305 313
95. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181
96. D.E. Nichols D.C. Dyer Lipophilicity and serotonin agonist activity in a series of 4- substituted mescaline analogues J. Med. Chem. 20 1977 299 301
97. D.E. Nichols C.D. Nichols Serotonin receptors Chem. Rev. 108 2008 1614 1641
98. D.E. Nichols R. Oberlender Structure-activity relationships of MDMA-like substances NIDA Res. Monogr. 94 1989 1 29
99. D.E. Nichols R. Oberlender Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann. N. Y. Acad. Sci. 600 1990 613 623
100. D.E. Nichols A.J. Hoffman R.A. Oberlender P. Jacob 3rd A.T. Shulgin Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class J. Med. Chem. 29 1986 2009 2015
101. D.E. Nichols S. Frescas D. Marona-Lewicka D.M. Kurrasch-Orbaugh Lysergamides of isomeric 2,4-dimethyl-azetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent, N,N-diethylly-sergamide (LSD) J. Med. Chem. 45 2002 4344 4349
102. R. Oberlender D.E. Nichols Drug discrimination studies with MDMA and amphetamine Psychopharmacology 95 1988 71 76
103. R. Oberlender D.E. Nichols (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity J. Pharmacol. Exp. Ther. 255 1990 1098 1106
104. A. Ouagazzal A.J. Grottick J. Moreau G.A. Higgins Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains Neuropsychopharmacology 25 2001 565 575
105. 2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats Psychopharmacology 124 1996 107 116
106. J.C. Parrish M.R. Braden E Gundy D.E. Nichols Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists J. Neurochem. 95 2005 1575 1584
107. N.J. Penington R.J. Reiffenstein Direct comparision of hallucinogenic phenethylamines and D-amphetamine on dorsal raphe neurons Eur. J. Pharmacol. 122 1986 373 377
108. R.C. Pfaff X. Huang D. Marona-Lewicka R. Oberlender D.E. Nichols Lysergamides revisited NIDA Res. Monogr. 146 1994 52 73
109. P.A. Pierce S.J. Peroutka Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex Psychopharmacology 97 1989 118 122
110. 2C receptors in CHO-K1 cells Br. J. Pharmacol. 128 1999 13 20
111. M.M. Rapport A.A. Green I.H. Paige Serum vasoconstrictor (serotonin) IV. Isolation and characterization J. Biol. Chem. 176 1948 1243 1251
112. J. Riba A. Rodriguez-Fornells M.J. Barbanog Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively Psychopharmacology 165 2002 18 28
113. 1a receptor agonists block prepulse inhibition of acoustic startle reflex J. Pharmacol. Exp. Ther. 263 1992 486 493
114. V.B. Risbrough V.L. Masten S. Caldwell M.P. Paulus M.J. Low M.A. Geyer Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice Neuropsychopharmacology 31 2006 2349 2358
115. 1B receptor Psychopharmacology 141 1999 154 161
116. M.D. Schechter MDMA as a discriminative stimulus: isomeric comparisons Pharmacol. Biochem. Behav. 27 1987 41 44
117. M.D. Schechter Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) Pharmacol. Biochem. Behav. 31 1988 817 824
118. 1A receptor agonists in the rat J. Pharmacol. Exp. Ther. 265 1993 572 579
119. R. Schreiber M. Brocco M.J. Millan Blockade of the discriminative stimulus effect of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risperidone Eur. J. Pharmacol. 264 1994 99 102
120. 1A agonists J. Pharmacol. Exp. Ther. 273 1995 101 112
121. R.E. Schultes A. Hofmann The Botany and Chemistry of Hallucinogens 1980 Charles C. Thomas Springfield, IL
122. J. Selken D.E. Nichols Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/−)-3,4-methylenedioxymethamphetamine (MDMA) in rats Pharmacol. Biochem. Behav. 86 2007 622 630
123. E. Shaw D.W. Woolley Some serotoninlike activities of lysergic acid diethylamide Science 124 1956 121 122
124. A.T. Shulgin Stereospecific requirements for hallucinogenesis J. Pharm. Pharmacol. 25 1973 271 272
125. A. Shulgin A. Shulgin PIHKAL A Chemical Love Story 1991 Transform Press Berkeley, CA
126. A.T. Shulgin T. Sargent C. Naranjo 4-Bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog Pharmacology 5 1971 103 107
127. M.T.A. Silva H.M. Calil Screening hallucinogenic drugs: systematic study of three behavioral tests Psychopharmacologia 42 1975 163 171
128. T.E. Sipes M.A. Geyer Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats Neuropharmacology 33 1994 441 448
129. 2C receptors Behav. Pharmacol. 6 1995 839 842
130. 2C, receptor Psychopharmacology 144 1999 248 254
131. R.L. Smith R.J. Barrett E. Sanders-Bush Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/−)DOI] in C57BL/6J mice Psychopharmacology 166 2003 61 68
132. S.H. Snyder S. Unger R. Blatchley C.F. Barfknecht Stereospecific actions of DOET (2,5-dimethoxy-4-ethylamphetamine) in man Arch. Gen. Psychiatry 31 1974 103 106
133. D.G. Spencer T. Glaser J. Traber Serotonin receptor subtype mediation of the interoceptive discriminative stimuli induced by 5-methoxy-N,N-dimethyltryptamine Psychopharmacology 93 1987 158 166
134. M. Spitzer B. Franke H. Walter J. Buechler A.P. Wunderlich M. Schwab K.A. Kovar L. Hermle G. Grôn Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans Neuropharmacology 41 2001 263 271
135. W.A. Stoll Lysergsäure-diathylamid, ein Phantastikum aus der Mutterkorngruppe Schweiz Arch. Neurol. Psychiatry 60 1947 279 323
136. R.J. Strassman Human psychopharmacology of, N,N-dimethyltryptamine Behav. Brain Res. 73 1996 121 124
137. 2 receptor as a site of action for LSD and phenylisopropyl amine hallucinogens Psychopharmacology 94 1988 213 216
138. M.D. Tricklebank C. Forler D.N. Middlemiss J.R. Fozard Subtypes of the 5-HT receptor mediating the behavioral responses to 5-methoxy-N,N-dimethyltryptamine in the rat Eur. J. Pharmacol. 117 1985 15 24
139. P.A. Tueting J. Metz B.K. Rhoades N.N. Boutros Pharmacologic challenge in ERP research Ann. N.Y. Acad. Sci. 658 1992 223 255
140. 2C receptor agonists Pharmacol. Biochem. Behav. 69 2001 643 652
141. F.X. Vollenweider K.L. Leenders C. Scharfetter P. Maguire O. Stadelmann J. Angst Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis Neuropsychopharmacology 16 1997 357 372
142. F.X. Vollenweider M.F. Vollenweider-Scherpenhuyzen A. Bäbler H. Vogel D. Hell Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport 9 1998 3897 3902
143. F.X. Vollenweider A. Gamma M. Liechti T. Huber Psychological and cardiovascular effects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naïve healthy volunteers Neuropsychopharmacology 19 1998 241 251
144. 2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval Neuropsychopharmacology 32 2007 1876 1887
145. 1 dopamine receptors Psychopharmacology 118 1995 401 409
146. J.G. Wettstein M. Host J.M. Hitchcock Selectivity of action of typical and atypical antipsychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) Prog. Neuro-Psychopharmacol. Biol. Psychiatry 23 1999 533 544
147. L.L. Wing G.S. Tapson M.A. Geyer 5HT-2 mediation of acute behavioral effects of hallucinogens in rats Psychopharmacology 100 1990 417 425
148. 1A receptors Pharmacol. Biochem. Behav. 65 2000 75 82
149. J.C. Winter J.R. Eckler R.A. Rabin Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli Psychopharmacology 172 2004 233 240
150. J.C. Winter K.C. Rice D.J. Amorosi R.A. Rabin Psilocybin-induced stimulus control in the rat Pharmacol. Biochem. Behav. 87 2007 472 480
151. R. Young N. Khorana T. Bondareva R.A. Glennon Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4-methylenedioxyamphetamine (MDMA) Pharmacol. Biochem. Behav. 82 2005 404 410